Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature-Reference-Cited by-同舟云学术

Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature

Published:2007-04-01 Issue:4 Volume:12 Page:451-464
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Grossi Francesco¹,Aita Marianna²,Follador Alessandro²,Defferrari Carlotta¹,Brianti Annalisa¹,Sinaccio Graziella¹,Belvedere Ornella²

Affiliation:

1. a Medical Oncology A, Disease Management Team – Lung Cancer, National Institute for Cancer Research, Genoa, Italy

2. b Department of Medical Oncology, University Hospital of Udine, Udine, Italy

Abstract

Learning Objectives After completing this course, the reader will be able to: Describe the new chemotherapy design strategies (i.e., sequential, alternating, and maintenance/consolidation chemotherapy).Identify potential advantages and drawbacks of these new strategies in advanced NSCLC.Discuss the results of clinical trials testing sequential, alternating, and maintenance/consolidation chemotherapy in advanced NSCLC. CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.12-4-451

Reference65 articles.

1. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003;Pfister;J Clin Oncol,2004

2. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy;Hanna;J Clin Oncol,2004

3. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis;Delbaldo;JAMA,2004

4. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer;Giaccone;J Clin Oncol,2005

5. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Consolidation chemotherapy after definitive concurrent chemoradiotherapy in patients with inoperable esophageal squamous cell carcinoma: a multicenter non-inferiority phase III randomized clinical trial;BMC Cancer;2024-03-07

2. Modern therapies of nonsmall cell lung cancer;Journal of Applied Genetics;2023-09-12

3. Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy;Current Oncology;2022-09-02

4. Addition of Induction or Consolidation Chemotherapy in Definitive Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone for Patients With Unresectable Esophageal Cancer: A Systematic Review and Meta-Analysis;Frontiers in Oncology;2021-09-13

5. Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone;Frontiers in Public Health;2021-06-18